ARS Pharmaceuticals, Inc. (SPRY) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $430.20M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-140.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $416.62M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-96.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $408.73M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $125.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $400.93M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-7.00K.
ARS Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $10.00K | $430.20M | $-140.00K | $-417.56M | $12.51M | 3 month · $12.80M | (m) |
| 2026-03-31 | $0.00 | $10.00K | $416.62M | $-96.00K | $-355.22M | $61.31M | 3 month · $7.83M | (m) |
| 2025-12-31 | $0.00 | $10.00K | $408.73M | $125.00K | $-294.60M | $114.26M | 12 month · $23.17M | (m) |
| 2025-09-30 | $0.00 | $10.00K | $400.93M | $-7.00K | $-253.28M | $147.66M | 3 month · $5.97M | (m) |
| 2025-06-30 | $0.00 | $10.00K | $394.49M | $-46.00K | $-202.13M | $192.32M | 3 month · $5.65M | (m) |
| 2025-03-31 | $0.00 | $10.00K | $386.14M | $72.00K | $-157.25M | $228.97M | 3 month · $5.54M | (m) |
| 2024-12-31 | $0.00 | $10.00K | $379.87M | $220.00K | $-123.31M | $256.80M | 12 month · $14.85M | (m) |
| 2024-09-30 | $0.00 | $10.00K | $373.87M | $339.00K | $-173.24M | $200.98M | 3 month · $3.70M | (m) |
| 2024-06-30 | $0.00 | $10.00K | $369.49M | $-145.00K | $-154.11M | $215.24M | 3 month · $3.37M | (m) |
| 2024-03-31 | $0.00 | $10.00K | $365.58M | $-124.00K | $-141.59M | $223.87M | 3 month · $3.31M | (m) |
| 2023-12-31 | $0.00 | $10.00K | $362.00M | $49.00K | $-131.30M | $230.76M | 12 month · $9.35M | (m) |
| 2023-09-30 | $0.00 | $9.00K | $361.57M | $-161.00K | $-124.14M | $237.28M | 3 month · $2.66M | (m) |
| 2023-06-30 | $0.00 | $9.00K | $357.99M | $-180.00K | $-109.27M | $248.55M | 3 month · $2.16M | (m) |
| 2023-03-31 | $0.00 | $9.00K | $352.98M | $68.00K | $-91.90M | $261.15M | 3 month · $2.25M | (m) |
| 2022-12-31 | $0.00 | $9.00K | $349.41M | $407.00K | $-76.94M | $272.89M | 12 month · $5.84M | 12 month · $223.00K |
| 2022-09-30 | $0.00 | $4.00K | $516.83M | $-1.62M | $-248.14M | $-50.16M | 3 month · $460.00K | (m) |
| 2022-06-30 | $0.00 | $4.00K | $510.61M | $-1.55M | $-230.27M | $-44.03M | 3 month · $356.00K | (m) |
| 2022-03-31 | $0.00 | $4.00K | $505.32M | $-1.25M | $-210.84M | $-38.26M | 3 month · $264.00K | (m) |
| 2021-12-31 | $0.00 | $3.00K | $10.98M | $0.00 | $-42.26M | $-31.27M | 12 month · $2.83M | (m) |
| 2021-09-30 | $0.00 | $4.00K | $494.92M | $-34.00K | $-162.75M | $332.13M | 3 month · $5.02M | (m) |
| 2021-06-30 | (m) | $4.00K | $489.74M | (m) | $-140.10M | $349.65M | 3 month · $4.73M | (m) |
| 2021-03-31 | (m) | $3.00K | $484.15M | (m) | $-115.60M | $368.55M | 3 month · $4.29M | (m) |
| 2020-12-31 | $0.00 | $3.00K | $479.61M | $0.00 | $-96.73M | $-14.05M | 12 month · $2.64M | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-78.25M | 3 month · $191.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-70.34M | 3 month · $128.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-64.00M | 3 month · $47.00K | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-58.78M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |